Kamada (KMDA) Competitors $6.05 0.00 (0.00%) (As of 12/24/2024 01:48 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends KMDA vs. TVTX, OCUL, DAWN, SEPN, NTLA, ARVN, SYRE, CALT, GYRE, and ANIPShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Travere Therapeutics (TVTX), Ocular Therapeutix (OCUL), Day One Biopharmaceuticals (DAWN), Septerna (SEPN), Intellia Therapeutics (NTLA), Arvinas (ARVN), Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), Gyre Therapeutics (GYRE), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry. Kamada vs. Travere Therapeutics Ocular Therapeutix Day One Biopharmaceuticals Septerna Intellia Therapeutics Arvinas Spyre Therapeutics Calliditas Therapeutics AB (publ) Gyre Therapeutics ANI Pharmaceuticals Kamada (NASDAQ:KMDA) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends. Is KMDA or TVTX more profitable? Kamada has a net margin of 9.92% compared to Travere Therapeutics' net margin of -172.75%. Kamada's return on equity of 6.30% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kamada9.92% 6.30% 4.49% Travere Therapeutics -172.75%-537.74%-55.65% Do insiders and institutionals have more ownership in KMDA or TVTX? 20.4% of Kamada shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 4.1% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, KMDA or TVTX? Kamada has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Does the MarketBeat Community believe in KMDA or TVTX? Kamada received 244 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 65.91% of users gave Kamada an outperform vote while only 57.04% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformKamadaOutperform Votes32165.91% Underperform Votes16634.09% Travere TherapeuticsOutperform Votes7757.04% Underperform Votes5842.96% Do analysts recommend KMDA or TVTX? Kamada currently has a consensus target price of $14.50, suggesting a potential upside of 139.67%. Travere Therapeutics has a consensus target price of $23.67, suggesting a potential upside of 38.16%. Given Kamada's stronger consensus rating and higher possible upside, equities research analysts plainly believe Kamada is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Travere Therapeutics 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Which has preferable earnings & valuation, KMDA or TVTX? Kamada has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$158.38M2.20$8.28M$0.2821.61Travere Therapeutics$203.45M6.57-$111.40M-$4.55-3.76 Does the media prefer KMDA or TVTX? In the previous week, Travere Therapeutics had 3 more articles in the media than Kamada. MarketBeat recorded 3 mentions for Travere Therapeutics and 0 mentions for Kamada. Travere Therapeutics' average media sentiment score of 1.16 beat Kamada's score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Kamada Neutral Travere Therapeutics Positive SummaryKamada beats Travere Therapeutics on 13 of the 18 factors compared between the two stocks. Ad StocksToTradeliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$347.75M$6.70B$5.24B$9.28BDividend YieldN/A2.98%5.12%4.28%P/E Ratio21.6110.4687.5417.25Price / Sales2.20206.681,164.33121.12Price / Cash14.2457.1543.3837.82Price / Book1.425.174.844.94Net Income$8.28M$151.96M$121.05M$225.76M7 Day Performance3.42%3.11%2.49%3.92%1 Month Performance4.13%-4.17%17.57%1.71%1 Year Performance-0.49%7.50%28.57%15.79% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada3.9402 of 5 stars$6.05flat$14.50+139.7%-0.7%$347.75M$158.38M21.61360Short Interest ↓TVTXTravere Therapeutics2.6744 of 5 stars$17.07-0.6%$23.67+38.6%+89.1%$1.33B$203.45M-3.75460Positive NewsOCULOcular Therapeutix3.7029 of 5 stars$8.46-0.5%$16.71+97.6%+101.2%$1.33B$61.44M-6.41267DAWNDay One Biopharmaceuticals1.6166 of 5 stars$12.58-1.6%$35.71+183.9%-15.7%$1.27B$101.95M-12.2160Positive NewsSEPNSepterna2.1161 of 5 stars$28.37+16.8%$43.67+53.9%N/A$1.26B$981,000.000.00N/ANTLAIntellia Therapeutics4.1436 of 5 stars$12.08-0.8%$54.94+354.8%-61.6%$1.23B$43.09M-2.22600ARVNArvinas2.1053 of 5 stars$17.90-3.1%$63.50+254.7%-52.7%$1.23B$161.10M-3.83445SYRESpyre Therapeutics1.8841 of 5 stars$23.37-2.1%$51.50+120.4%+28.5%$1.20B$890,000.00-3.13100CALTCalliditas Therapeutics AB (publ)0.0668 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180GYREGyre Therapeutics0.4682 of 5 stars$12.40+11.3%N/A-59.9%$1.16B$105.03M0.0040Short Interest ↑Gap DownANIPANI Pharmaceuticals4.6953 of 5 stars$54.16+1.5%$77.71+43.5%+1.4%$1.14B$555.46M-98.47642Positive News Related Companies and Tools Related Companies Travere Therapeutics Alternatives Ocular Therapeutix Alternatives Day One Biopharmaceuticals Alternatives Septerna Alternatives Intellia Therapeutics Alternatives Arvinas Alternatives Spyre Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Gyre Therapeutics Alternatives ANI Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KMDA) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
